Engineering antioxidant and anti-inflammatory biohybrid matrices for organ repair: from redox-immune design principles to clinical translation

Abstract

Successful organ repair requires more than the delivery of a structurally supportive scaffold to the site of injury. Tissue injury establishes a self-propagating microenvironment where oxidative stress and inflammation reciprocally reinforce each other, causing degradation of implanted materials, inactivation of bioactive cargo, and spread of damage to surrounding healthy tissue. This pathological cycle questions the basic assumption of conventional scaffold design, where mechanical support is considered sufficient and the host microenvironment passive. Rather, a larger body of evidence suggests that the scaffold is an active participant in the injury response, one that can scavenge reactive oxygen species (ROS), restore redox homeostasis, and re-direct inflammation toward resolution rather than chronicity. This review synthesizes the design rationale, bioactive ingredients, and matrix platforms underpinning this emerging class of antioxidant and anti-inflammatory biohybrid materials, with particular emphasis on extracellular vesicle (EV)-loaded constructs, natural-extract systems, endogenous-agent biohybrids, and surface-modified or stimuli-responsive matrices, which can be programmed to release in spatiotemporal fashion. The current analysis argues that the ROS-NF-kB-Nrf2 axis represents the major, but underutilized, opportunity in the field and evaluates each construct class with respect to this coupling, rather than in isolation, in contrast to previous reviews, which treat antioxidant and anti-inflammatory approaches as parallel design paths. The evidence supporting these strategies for cardiac, hepatic, renal, neural, and cutaneous repair is critically evaluated, along with the preclinical models employed to validate them and the manufacturing, regulatory, and clinical-translation hurdles that currently limit their application. The principal obstacles to clinical deployment, rather than any deficit in mechanistic rationale, are identified as persistent gaps: irreproducible potency assays, animal models that poorly represent the aged and comorbid patients most in need of therapy, and unresolved trade-offs between payload protection and bioactivity. The review concludes that next-generation regenerative biomaterials for pathologically stressed organs will require biomimetic matrices engineered for precise spatiotemporal control over both antioxidant and immunomodulatory functions and that achieving this will depend less on the discovery of new bioactive agents than on solving the integration, standardization, and validation challenges that currently separate promising constructs from clinical practice.